<DOC>
	<DOCNO>NCT01204203</DOCNO>
	<brief_summary>The primary objective trial determine response rate single agent zoledronic acid use composite criterion include EORTC modify RECIST criterion EORTC tumor response criterion 18F-FDG PET scan .</brief_summary>
	<brief_title>Pilot Study Bisphosphonate Therapy ( Zoledronic Acid ) Patients With Malignant Mesothelioma ( UAB 0901 )</brief_title>
	<detailed_description>This pilot study examine effect bisphosphonate ( zoledronic acid ) patient malignant mesothelioma . Evaluation limit patient standard ( CT scan ) functional instrument ( FDG PET Scans ) tumor assessment administration standard dose zoledronic acid ( 4 mg IV every 3 week ) . We also explore biologic effect zoledronic acid patient use new serum marker well several blood level marker .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Males female &gt; 18 year age Life expectancy least 2 month Histologically confirm unresectable malignant pleural mesothelioma ( MPM ) Measurable disease CT Scan criterion and/or positive metabolic activity 18FFDG PET Scan criterion screen ECOG Performance Status 02 Laboratory clinical result within 2 week prior Day 1 must follow : 1 . ANC ≥ 1.5 x 109/L 2 . Platelet Count ≥ 100 x 109/L 3 . Hemoglobin ≥ 9g/dL 4 . Serum bilirubin ≤ 1.5 x upper limit normal ( ULN ) 5 . AST ≤ 2.5 x ULN 6 . ALT ≤ 2.5 x ULN 7 . ALKP ≤ 3 x ULN 8 . Serum creatinine ≤ 1.8mg/dL 9 . Calculated Serum Creatinine Clearance 40 &gt; 60ml/min Female subject childbearing potential male subject must surgically sterile consent use medically acceptable method contraception throughout trial . Willing able provide write informed consent . Known central nervous system ( CNS ) tumor involvement Evidence active malignancy require treatment Clinically significant heart disease ( e.g. , congestive heart failure New York Heart Association Class 3 4 angina well controlled medication , myocardial infarction within 6 month ) Known infection HIV hepatitis Clinically significant arrhythmia demonstrate electrocardiogram ( ECG ) . Note : subject chronic atrial arrhythmia , i.e. , atrial fibrillation paroxysmal supraventricular tachycardia ( SVT ) eligible . Active , serious systemic disease , include active bacterial fungal infection . Subjects undergo invasive dental procedure , significant periodontal disease history osteonecrosis jaw . Treatment within 4 week start trial systemic anticancer therapy . Breastfeeding , pregnant , likely become pregnant clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>mesothelioma</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>zometa</keyword>
	<keyword>bisphosphonate therapy</keyword>
	<keyword>CT scan</keyword>
	<keyword>PET scan</keyword>
</DOC>